{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T11:40:02Z","timestamp":1719488402605},"reference-count":38,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1080\/13696998.2017.1387120","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T11:14:30Z","timestamp":1506683670000},"page":"182-188","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs"],"prefix":"10.1080","volume":"21","author":[{"given":"V. N.","family":"Joish","sequence":"first","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., Basking Ridge, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Frech","sequence":"additional","affiliation":[{"name":"Former Employee of Lexicon Pharmaceuticals, Basking Ridge, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lapuerta","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., Basking Ridge, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,10,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt377"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-010-0158-4"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.182.3.1820559"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30110-9"},{"key":"CIT0006","unstructured":"Food and Drug Administration. Orphan drugs, 21 C.F.R. Sect. 316.300(1)(d). Silver Spring, MD, USA: U.S. Food and Drug Administration; 2017"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200306000-00004"},{"key":"CIT0008","unstructured":"National Cancer Institute. Gastrointestinal carcinoid tumors treatment. Bethesda, MD, USA: NCI. Available at: https:\/\/www.cancer.gov\/types\/gi-carcinoid-tumors\/hp\/gi-carcinoid-treatment-pdq#link\/_219_toc"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i6.2118"},{"key":"CIT0010","unstructured":"National Comprehensive Cancer Network. NCCN guidelines, version 2.02. Neuroendocrine tumours. Fort Washington, PA, USA: NCCN. 2014. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"CIT0011","unstructured":"Novartis Pharmaceuticals Corporation. Sandostatin\u00ae (octreotide acetate) Prescribing Information. East Hanover, NJ, USA: Novartis Pharmaceuticals; 2012. Available at: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/sandostatin_inj.pdf"},{"key":"CIT0012","unstructured":"Novartis Pharmaceuticals Corporation. Sandostatin LAR\u00ae (octreotide acetate) Prescribing Information. East Hanover, NJ, USA: Novartis Pharmaceuticals; 2012. Available at: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/sandostatin_lar.pdf"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.60311"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.132670"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.4155\/cli.15.10"},{"key":"CIT0017","volume-title":"Xermelo\u00ae (telotristat ethyl) Prescribing Information","author":"Lexicon Pharmaceuticals, Inc.","year":"2017"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2780"},{"key":"CIT0019","first-page":"S21","volume":"23","author":"Schafer J","year":"2017","journal-title":"J Manag Care Pharm"},{"key":"CIT0020","unstructured":"Ollendorf DA, Chapman R, Pearson SD. Assessing the effectiveness and value of drugs for rare conditions. Institute for Clinical and Economic Review Technical Brief for the ICER Orphan Drug Assessment and Pricing Summit. Boston, MA, USA: Institute for Clinical and Economic Review; May 2017. Available at: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/02\/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017.pdf"},{"key":"CIT0021","unstructured":"National Institute for Health and Care Excellence. NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE\u2019s technology appraisal and highly specialised technologies programmes. London, United Kingdom: National Institute for Health and Care Excellence; 2017. Available at: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/board-paper-TA-HST-consultation-mar-17-HST-only.pdf"},{"key":"CIT0022","unstructured":"Institute for Clinical and Economic Review. Proposed adaptation of the ICER value framework for the assessment of treatments for ultra-rare conditions. Boston, MA, USA: Institute for Clinical and Economic Review; July 2017. Available at: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/05\/ICER_Proposed_VAF_Adaptations_Orphan_Drugs_072517.pdf"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03839.x"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04083.x"},{"issue":"7","key":"CIT0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mds295","volume":"23","author":"\u00d6berg K","year":"2012","journal-title":"Ann Oncol"},{"key":"CIT0026","first-page":"81","volume":"6","author":"Strosberg J","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.07.025"},{"key":"CIT0028","first-page":"S24","volume":"22","author":"Burton T","year":"2016","journal-title":"J Manag Care Pharm"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3182328045"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.05.003"},{"key":"CIT0031","unstructured":"Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry. Silver Spring, MD, USA: U.S. Food and Drug Administration. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.3.342"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04620.x"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7563.340"},{"key":"CIT0035","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"Gold MR","year":"1996"},{"key":"CIT0036","unstructured":"Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017\u20132019. Boston, MA, USA. Available at: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/06\/ICER-value-assessment-framework-update-FINAL-062217.pdf"},{"key":"CIT0037","unstructured":"Pavel M, H\u00f6rsch D, Anthony L, et\u00a0al. Patients interviewed in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome. Presented at the Annual Meeting of the European Neuroendocrine Tumor Society (ENETS); March 9\u201311, 2016; Barcelona, Spain"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.583"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2017.1387120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T11:00:13Z","timestamp":1719486013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2017.1387120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,9]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2,1]]}},"alternative-id":["10.1080\/13696998.2017.1387120"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2017.1387120","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}